Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MSTX breaking out now in gap zone
MSTX I agree. This one looks ready to break out.
Das iel goe, das kei tof!!
Das iel goe, das kei tof!!
Das iel goe, das kei tof!!
I was there on a weekendtrip last weekend
I am from Antwerp
Oh! Where are you from?
VICL News!! Publication Highlights Milestone in Vaccine Development
ASP0113 is First DNA Vaccine to Reach Phase 3 Clinical Trial
SAN DIEGO, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the publication of a new article1 in a special DNA vaccine issue of the journal Vaccines detailing the development process from initial product concept to Phase 3 trial initiation for ASP0113 (TransVaxâ„¢), Vical's investigational therapeutic vaccine designed to control cytomegalovirus (CMV) in transplant recipients. Vical and Astellas Pharma Inc. (TSE:4503) ("Astellas") entered into exclusive worldwide license agreements in 2011 to develop and commercialize ASP0113.
"Vical has been a pioneer in the development of DNA vaccines since the discovery of plasmid DNA utility in the late 1980s," said Larry R. Smith, Ph.D., Vice President, Vaccine Research at Vical and lead author of the new publication. "The recent initiation of the Phase 3 trial of ASP0113 marks a major achievement for the company and a significant milestone in the vaccine field. We are particularly pleased to share the recognition for this important 'first' with our partners at Astellas who have assumed responsibility for the advancement of ASP0113. We are excited by the potential to address a serious medical need for immunosuppressed transplant patients whose recovery is threatened by CMV."
MSTX 0.5251 in PM Woo hoooo!!
CXM has compliance issues also for financial impairment. They are at risk being unless they raised enough cash during this recent run up we should see a pr real soon with another 3 month extension.
BONE delayed or not it's a large buy well above the last trade. We'll find out today if there is a continuation in price or not
VICL I am in and like the chart... waiting patiently
MSTX we need news!!
DCTH glad you made money!! I mentioned it on Friday but I sold today at 0.50.
Set your stops and let her run...
Cheers!
CXM I want it to go much higher.... and it could with the right news
Awaiting
CE marking
Insurance Reimbursement
Results from Generx in phase III
MSTX going green.. is it time?
BONE now 0.80
DCTH yes, very happy I sold at 0.50
Congrats!!! Fabulous!!
TWGP noticed your msg y'day and it looks good. I am adding VICL and MSTX. At some point they have to move. GL
Cheers!
DCTH hope so too....Posted it on Friday
DCTH hit .5141 PM woooow
DCTH could run hard!! Focused on liver cancer treatment
THE BIG PICTURE: Delcath is a specialty-drug and medical-device company focused on cancer treatments. It makes a catheter system that treats cancer by delivering high doses of chemotherapy drugs directly to the liver while controlling exposure to the rest of the body.
The FDA is reviewing several uses of the technology, including treatment of inoperable ocular melanoma, a cancer of the eye that can spread to the liver. The system is available in Europe for that use under the name Chemosat.
DCTH could run hard!! Focused on liver cancer treatment
THE BIG PICTURE: Delcath is a specialty-drug and medical-device company focused on cancer treatments. It makes a catheter system that treats cancer by delivering high doses of chemotherapy drugs directly to the liver while controlling exposure to the rest of the body.
The FDA is reviewing several uses of the technology, including treatment of inoperable ocular melanoma, a cancer of the eye that can spread to the liver. The system is available in Europe for that use under the name Chemosat.
DCTH I am for
DCTH hurrayyyy!!
VICL take a look, could go any day imo
BONE now 0.7459 +11,79%
BONE at 0.72 about to break!!
Bone gap filled, needs to break 0.72
BONE 0.70 +16,59%
BONE nhod
BONE exceptional volume, new CEO at the helm... could move much higher
DCTH building
VICL take a look, looks like it is coming off low
DCTH is up 20.40% at $0.36 in pre-market trading, following the release on the U.S. Food and Drug Administration's website that the company's drug, melphalan hydrochloride, has been granted an orphan drug designation.
DCTH me too. I saw a mention on twitter about orphan drug designation news out. If true this could run
Dcth up AH...anyone following?
MSTX slowly but surely moving higher
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads